In a study, patients with neuropathic pruritus showed significantly higher rates of anxiety, depression, sleep disorders, type 2 diabetes, obesity, and falls than healthy individuals, in a study that ...

A recently published case series illustrates how a treatment approved last year for two conditions associated with pruritus could be useful in alleviating itch in patients with a broad variety of ...

Topical ruxolitinib offers a promising treatment for dermatologic conditions with fewer adverse events than oral JAK inhibitors. FDA approvals for ruxolitinib cream in atopic dermatitis and vitiligo ...

Pruritus drug developer Cara Therapeutics kicked off the year halving its headcount, and the biotech has now found a new home via a merger with fibrosis disease-focused Tvardi Therapeutics. The merger ...

Every dermatologist encounters maddeningly pruritic patients at their wit's end. Our deficient understanding of and treating dermatology's essential symptom is even more exasperating. The following is ...

Cara Therapeutics said its Notalgia Paresthetica drug failed in clinical trials. The company is looking at strategic alternatives. Get daily-updated rankings across momentum, growth, value, trends, ...

The good news for Sarepta Therapeutics Inc. is bad news for Pfizer Inc. as the phase III study of its mini-dystrophin gene therapy in Duchenne muscular dystrophy has missed its primary endpoint. Now ...

June 12 (Reuters) - Cara Therapeutics (CARA.O), opens new tab said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its oral drug did ...

– Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics (CARA), Inc. , a development-stage ...

Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara ...